# Subhanu Saxena

> Subhanu Saxena is a Series A investor at New Rhein backing Medical and Manufacturing. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [New Rhein](https://shizune.co/investors/profile/new-rhein-healthcare)
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/subhanu-saxena-17b402103

Subhanu Saxena is a Series A investor at New Rhein focused on Medical and Manufacturing. Subhanu Saxena is the Global Chief Executive Officer and Managing Director at Cipla Inc. since February 2013. Subhanu was previously Head of Global Product Strategy and Commercialisation at Novartis, where he was also part of the Swiss pharma giant's executive committee. Prior to this most recent position at Novartis, Subhanu was ChiefExecutive Officer and Country President of Novartis UK. Subhanu also has wide non-healthcare experience, working with companies such as Citicorp, the Boston Consulting Group and PepsiCo across markets in Europe, North America, Africa and Asia. Subhanu has a Graduate degree in Engineering from Oxford University and an MBA from INSEAD, France.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 0% |
| Manufacturing | 1 | 0% |
| Pharmaceutical | 1 | 0% |

## About New Rhein

VC Fund · Philadelphia, United States

New Rhein is a venture capital firm focused on healthcare therapeutics and medical devices. Its partners and associates are former industry executives with operational and transactional experience. New Rhein invests in businesses that utilize proven products in new applications (e.g., new indications, new dosage forms, 505(b2)). The companycompiles syndicates of operationally focused investors who together bring a wealth of experience and a broad network of relationships to support its portfolio companies in the development, regulatory, reimbursement, marketing, and/or contract manufacturing. New Rhein provides an understanding of what would be attractive to strategic partners and works backward to help its portfolio companies build their value proposition. Prior New Rhein investments have included ophthalmic pharmaceuticals, molecular diagnostics, and respiratory drug/device inhalers.

4 contacts available at New Rhein.

| Name | Title | Profile |
| --- | --- | --- |
| Ivan Gergel | Managing Partner | https://shizune.co/investors/profile/ivan-gergel |
| Nishant Rastogi | VP | https://shizune.co/investors/profile/nishant-rastogi |
| Paul Navarre | Executive in Residence | https://shizune.co/investors/profile/paul-navarre |
| Subhanu Saxena | Managing Partner | https://shizune.co/investors/profile/subhanu-saxena |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Subhanu Saxena invest in?

Subhanu Saxena invests primarily in Medical, Manufacturing and Pharmaceutical startups, most often at Series A stage. Most of the 0 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co